Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation

Clinical Transplantation

Volumn 24, Issue 6, 2010, Pages 855-861

  Yanagimachi, Masakatsu ^a   Naruto, Takuya ^a   Tanoshima, Reo ^a   Kato, Hiromi ^a   Yokosuka, Tomoko ^a   Kajiwara, Ryosuke ^a   Fujii, Hisaki ^a   Tanaka, Fumiko ^a   Goto, Hiroaki ^a   Yagihashi, Tatsuhiko ^b   Kosaki, Kenjiro ^b   Yokota, Shumpei ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ABCB1; Calcineurin inhibitor; CYP3A5; Neurotoxicity; Polymorphism

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A5; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN DISEASE; CHILD; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; NEUROTOXICITY SYNDROMES; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 78649918904     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01181.x     Document Type: Article

References (26)

1. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000: 14: 190.
2. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994: 331: 1110.
3. Hesselink DA, Van Gelder T, Van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 2005: 6: 323.
4. Hauser IA, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005: 16: 1501.
5. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001: 27: 383.
6. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000: 97: 3473.
7. Yamauchi A, Ieiri I, Kataoka Y et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002: 74: 571.
8. Kanekiyo T, Hara J, Matsuda-Hashii Y et al. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol 2005: 81: 264.
9. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995: 15: 825.
10. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999: 14: 143.
11. Saito K, Miyake S, Moriya H et al. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem 2003: 36: 511.
12. González JR, Armengol L, Solé X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007: 23: 644.
13. Lake SL, Lyon H, Tantisira K et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003: 55: 56.
14. Horinouchi M, Sakaeda T, Nakamura T et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002: 19: 1581.
15. Yokogawa K, Takahashi M, Tamai I et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in MDR1A knockout mice. Pharm Res 1999: 16: 1213.
16. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004: 26: 180.
17. Dulucq S, Bouchet S, Turcq B et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008: 112: 2024.
18. Aarnoudse AJ, Dieleman JP, Visser LE et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 2008: 18: 299.
19. Kiemeneij IM, De Leeuw FE, Ramos LM, Van Gijn J. Acute headache as a presenting symptom of tacrolimus encephalopathy. J Neurol Neurosurg Psychiatry 2003: 74: 1126.
20. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996: 334: 494.
21. Kuypers DR, De Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not ABCB1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007: 82: 711.
22. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 2007: 8: 297.
23. Hesselink DA, Van Schaik RH, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003: 74: 245.
24. Dai Y, Hebert MF, Isoherranen N et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006: 34: 836.
25. Schleuning M, Judith D, Jedlickova Z et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009: 43: 717.
26. Cutler C, Antin JH. Novel drugs for the prevention and treatment of acute GVHD. Curr Pharm Des 2008: 14: 1962.